Is the adenosine A2B ‘biased’ receptor a valuable target for the treatment of pulmonary arterial hypertension?
| Autor: | A.P. Fontes‐Sousa, Eduardo Martins-Dias, Mafalda Bessa-Gonçalves, Paulo Correia-de-Sá, Bruno Bragança |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pharmacology Lung business.industry medicine.disease Pulmonary hypertension Adenosine receptor Adenosine Cell membrane 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Tissue remodeling Drug Discovery medicine Signal transduction Receptor business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Drug Discovery Today. 23:1285-1292 |
| ISSN: | 1359-6446 |
| Popis: | Pulmonary arterial hypertension (PAH) is a maladaptive disorder characterized by increased pulmonary vascular resistance leading to right ventricular failure and death. Adenosine released by injured tissues, such as the lung and heart, influences tissue remodeling through the activation of adenosine receptors. Evidence regarding activation of the low-affinity A2BAR by adenosine points towards pivotal roles of this receptor in processes associated with both acute and chronic lung diseases. Conflicting results exist concerning the beneficial or detrimental roles of the A2B 'biased' receptor in right ventricular failure secondary to PAH. In this review, we discuss the pros and cons of manipulating A2BARs as a putative therapeutic target in PAH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect